The global diabetic retinopathy market is estimated to grow at a CAGR of over 6% during the forecast period. Diabetes is one of the critical causes of blindness and blurred vision in adults. As the number of peoples suffering from diabetes increases, the prevalence of diabetic retinopathy increases. In the early stages, diabetic retinopathy may show symptoms such as changes to eyesight and vision and can damage eyes, and if not treated properly, it can damage vision permanently.

The factors that contribute to the growth of the global diabetic retinopathy market includes the increase in the number of peoples suffering from diabetes. In diabetes, excess of sugar intake leads to blockage of the small blood vessels that moistures the retina, and it also cuts off the blood supply which in turn results in the eye attempting to grow new blood vessels; nevertheless, these new blood vessels don't mature properly and leak easily that damages the eye. Thus, increased sugar levels in diabetes lead to the damaging of the eye.

Furthermore, increasing disposable incomes, availability of advanced technology and laser procedures along with the quick recovery options is likely to promote patients’ willingness to adopt surgical treatments which fuel the growth of the market. However, the high cost of treatment may challenge the growth of the global diabetic retinopathy market during the forecast period.

Segmental Outlook

The global diabetic retinopathy is segmented into type and management. Based on the type, the market is bifurcated into proliferative diabetic retinopathy and non-proliferative diabetic retinopathy. Based on the management, the market is segmented into anti-VEGF, intraocular steroid injection, laser surgery, and vitrectomy.

Global Diabetic Retinopathy Market, by Type 2018 (%)

Non - Proliferative Diabetic Retinopathy to Hold Significant Share in the Market

Based on the type, non-proliferative diabetic retinopathy is estimated to hold a significant share in the global diabetic retinopathy market during the forecast period. Non-proliferative diabetic retinopathy is among the most common cause of blindness in most of the people suffering from diabetes. It is also less chronic in comparison with proliferative diabetic retinopathy and is more prevalent in the patients that come under the age group of 40-60 years. In addition, this can be cured by medications and treatments in its early stages, therefore non-proliferative diabetic retinopathy is expected to hold a significant share. Whereas, proliferative diabetic retinopathy is the advanced stage of diabetic eye diseases and requires surgical intervention. Additionally, it is most common in the age group of 65 and above, in which most of the peoples refuse for the surgical treatments that may lower the pace of the proliferative diabetic retinopathy growth in the market during the forecast period.  

Regional Outlook

The global diabetic retinopathy market is geographically segmented into North America, Europe, Asia-Pacific and the Rest of the World. North America is expected to hold a significant share in the global market during the forecast period. This is attributed to the increased prevalence of diabetes in the region along with demands for medications and surgical components for the treatment. According to the Centers for Disease Control and Prevention and the Department of Health and Human Services headquartered in Atlanta, Georgia, stated that diabetic retinopathy is among the common diseases.From 2010 to 2050, the number of Americans with diabetic retinopathy is expected to nearly double, from 7.7 million to 14.6 million. Thus, the increased prevalence of diabetes retinopathy leads to growth opportunities for the market during the forecast period.

Global Diabetic Retinopathy Market, by Region 2018 (%)

Market Players Outlook

The prominent players operating in the global diabetic retinopathy market include F. Hoffmann-La Roche AG, Boehringer Ingelheim International GmbH, Regeneron Pharmaceuticals Inc., Oxurion N.V., Novartis International AG, Pfizer Inc., and many others.These are the key companies adopting several organic and inorganic growth strategies such as product launches & developments, partnerships, agreements, and acquisitions to strengthen their product portfolios and maintain a competitive position in the global diabetic retinopathy market. For instance, in April 2019, Novartis International AG received approval for its ophthalmic drug named, Brolucizumab. Such approvals for the manufacturing of novel drugs will enhance the company’s product portfolio and sales.

The Report Covers

• Market value data analysis of 2018 and forecast to 2025.
• Annualized market revenues ($ million) for each market segment.
• Country-wise analysis of major geographical regions.
• Key companies operating in the global diabetic retinopathy market. Based on the availability of data, information related to pipeline products, and relevant news is also available in the report.
• Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
• Analysis of market-entry and market expansion strategies.
• Competitive strategies by identifying ‘who-stands-where’ in the market.